Abbvie Inc. (ABBV) Files Form 4 Insider Selling : Laura J Schumacher Sells 186,106 Shares

Abbvie Inc. (ABBV): Laura J Schumacher , Executive Vice President of Abbvie Inc. sold 186,106 shares on Jun 24, 2016. The Insider selling transaction was reported by the company on Jun 28, 2016 to the Securities and Exchange Commission. The shares were sold at $60.07 per share for a total value of $11171173 , the company said in a SEC Form 4 Filing.

Other Insider transactions have been reported by the company according to SEC Form 4, on Jun 3, 2016, Richard A Gonzalez (Chairman of the Board and CEO) sold 285,953 shares at $63.87 per share price.On May 12, 2016, Timothy J. Richmond (SVP, Human Resources) sold 21,583 shares at $63.52 per share price.Also, On May 12, 2016, Thomas A. Hurwich (VP, Controller) sold 6,000 shares at $63.60 per share price.On May 12, 2016, Carlos Alban (EVP, Commercial Operations) sold 47,438 shares at $63.52 per share price.

Shares of AbbVie Inc (ABBV) ended Monday, Jun 27, 2016 session in red amid volatile trading. The shares closed down -1.18 points or -1.97% at $58.68 with 79,47,017 shares getting traded. Post opening the session at $59.38, the shares hit an intraday low of $58.329 and an intraday high of $59.68 and the price vacillated in this range throughout the day. The company has a market cap of $94,907 M and the number of outstanding shares has been calculated to be 1,61,73,58,600 shares. The 52-week high of AbbVie Inc is $71.6 and the 52-week low is $45.45.

AbbVie Inc Money Flow Index Chart

On Jun 16, 2016, AbbVie Inc announced a cash dividend of $0.5700. The company’s management has announced Jul 13, 2016 as the ex-dividend date and fixed the record date on Jul 15, 2016. The payable date has been fixed on Aug 15, 2016.

Company has been under the radar of several Street Analysts.AbbVie Inc is Downgraded by Morgan Stanley to Equal-Weight. Earlier the firm had a rating of Overweight on the company shares. The Rating was issued on Jun 8, 2016.AbbVie Inc is Initiated by Societe Generale to Sell and the brokerage firm has set the Price Target at $47. The Rating was issued on Apr 6, 2016.

AbbVie Inc. (AbbVie) is a global research-based biopharmaceutical company. The Company develops and markets therapies that address a range of diseases. The Company’s products are focused on treating conditions such as chronic autoimmune diseases including rheumatoid arthritis psoriasis and Crohn’s disease; hepatitis C (HCV); human immunodeficiency virus (HIV); endometriosis; thyroid disease; Parkinson’s disease; complications associated with chronic kidney disease and cystic fibrosis and other health conditions such as low testosterone. AbbVie also has a pipeline of new medicines including over 30 compounds or indications in Phase II or Phase III development across a range of medical specialties such as immunology virology/liver disease oncology renal disease neurological diseases and women’s health. The Company’s product portfolio includes HUMIRA HCV products Additional Virology products Metabolics/Hormones products Endocrinology products and other products.

Leave a Reply

AbbVie Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on AbbVie Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.